Clinical Trial Update: An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP) [Phase 2]

View source ↗

Summary

Open-label Phase 2 safety study for lusutrombopag in adults with chronic immune thrombocytopenia (ITP) has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• lusutrombopag (lusutrombopag)

Snippet

Sponsor: Shionogi | Conditions: Immune Thrombocytopenia | Phase 2 | Status: TERMINATED | Results posted: 2021-02-26